Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer.
Gold nanorods are effective photothermal agents in diagnosis and treatment of cancer due to their specific near-infrared laser absorption. However, tumor photothermal therapy by nanorods alone is lack of targeting. Here, we described a novel nanocomplex made up of gold nanorods, porphyrin, and trastuzumab, called TGNs and investigated the TGN-mediated photothermal therapy as a potential alternative treatment of targeting HER2-positive breast cancers. By conjugating trastuzumab and porphyrin to the surface of gold nanorods, we have increased the targeting specificity and amplified the detecting effectiveness at the same time. TGN-mediated photothermal ablation by near-infrared laser led to a selective destruction of HER2-positive cancer cells and significantly inhibited tumor growth in mouse models bearing HER2 over-expressed breast cancer xenograft with less toxicity. Moreover, TGNs provided better therapeutic efficacy in comparison with the conventional molecule targeted therapy. Our current data suggest a highly promising future of TGNs for its therapeutic application in trastuzumab-resistant breast cancers.
Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin 150081, Heilongjiang, China.
Xinmei
X
Kang
School of Life Science of Technology, Harbin Institute of Technology, Harbin 150081, Heilongjiang, China.
Ximing
X
Guo
Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin 150081, Heilongjiang, China.
Xingjian
X
Niu
Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin 150081, Heilongjiang, China.|Heilongjiang Academy of Medical Sciences, Harbin 150081, Heilongjiang, China.
Weiwei
W
An
School of Life Science of Technology, Harbin Institute of Technology, Harbin 150081, Heilongjiang, China.
Suhan
S
Li
Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin 150081, Heilongjiang, China.|Heilongjiang Academy of Medical Sciences, Harbin 150081, Heilongjiang, China.
Zhaoliang
Z
Liu
Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin 150081, Heilongjiang, China.|Heilongjiang Academy of Medical Sciences, Harbin 150081, Heilongjiang, China.
Yue
Y
Yang
School of Life Science of Technology, Harbin Institute of Technology, Harbin 150081, Heilongjiang, China.
Na
N
Wang
Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin 150081, Heilongjiang, China.
Qicheng
Q
Jiang
Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin 150081, Heilongjiang, China.|Heilongjiang Academy of Medical Sciences, Harbin 150081, Heilongjiang, China.
Caichuan
C
Yan
Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin 150081, Heilongjiang, China.
Hui
H
Wang
Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin 150081, Heilongjiang, China.|Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin 150081, Heilongjiang, China.|Heilongjiang Academy of Medical Sciences, Harbin 150081, Heilongjiang, China.
Qingyuan
Q
Zhang
D000818:Animals; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000628:therapy*; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage; D006046:Gold / Q000008:administration & dosage*; D064593:Heterografts; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D051379:Mice; D058990:Molecular Targeted Therapy / Q000379:methods; D043942:Nanotubes; D009368:Neoplasm Transplantation; D010789:Phototherapy / Q000379:methods*; D011166:Porphyrins / Q000008:administration & dosage*; D000068878:Trastuzumab / Q000008:administration & dosage*; D016896:Treatment Outcome
D000074322:Antineoplastic Agents, Immunological; D004337:Drug Carriers; D011166:Porphyrins; D006046:Gold; D000068878:Trastuzumab